EA199901097A1 - Прогнозирование воспалительного заболевания, ассоциированного с полиморфизмом генных локусов il-1 - Google Patents

Прогнозирование воспалительного заболевания, ассоциированного с полиморфизмом генных локусов il-1

Info

Publication number
EA199901097A1
EA199901097A1 EA199901097A EA199901097A EA199901097A1 EA 199901097 A1 EA199901097 A1 EA 199901097A1 EA 199901097 A EA199901097 A EA 199901097A EA 199901097 A EA199901097 A EA 199901097A EA 199901097 A1 EA199901097 A1 EA 199901097A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
inflammatory disorder
susceptibility
polymorphism
prediction
Prior art date
Application number
EA199901097A
Other languages
English (en)
Russian (ru)
Inventor
Гордон Дафф
Анджела Кокс
Никола Джэйн Кэмп
Франческо Саверио Де Джовине
Original Assignee
Интерлейкин Джинетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интерлейкин Джинетикс, Инк. filed Critical Интерлейкин Джинетикс, Инк.
Publication of EA199901097A1 publication Critical patent/EA199901097A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA199901097A 1997-05-29 1998-05-21 Прогнозирование воспалительного заболевания, ассоциированного с полиморфизмом генных локусов il-1 EA199901097A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711040.7A GB9711040D0 (en) 1997-05-29 1997-05-29 Prediction of inflammatory disease
PCT/GB1998/001481 WO1998054359A1 (en) 1997-05-29 1998-05-21 Prediction of inflammatory disease associated with il-1 geneloci polymorphisms

Publications (1)

Publication Number Publication Date
EA199901097A1 true EA199901097A1 (ru) 2000-06-26

Family

ID=10813199

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199901097A EA199901097A1 (ru) 1997-05-29 1998-05-21 Прогнозирование воспалительного заболевания, ассоциированного с полиморфизмом генных локусов il-1

Country Status (19)

Country Link
US (4) US6268142B1 (OSRAM)
EP (1) EP0983385B1 (OSRAM)
JP (1) JP2002500513A (OSRAM)
CN (1) CN1177059C (OSRAM)
AR (1) AR016754A1 (OSRAM)
AT (1) ATE462800T1 (OSRAM)
AU (1) AU755107B2 (OSRAM)
BR (1) BR9809183A (OSRAM)
CA (1) CA2291731A1 (OSRAM)
DE (1) DE69841588D1 (OSRAM)
EA (1) EA199901097A1 (OSRAM)
ES (1) ES2342992T3 (OSRAM)
GB (1) GB9711040D0 (OSRAM)
IL (1) IL133128A0 (OSRAM)
NO (1) NO995803L (OSRAM)
PL (1) PL337080A1 (OSRAM)
TW (1) TWI236502B (OSRAM)
WO (1) WO1998054359A1 (OSRAM)
ZA (1) ZA984490B (OSRAM)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6720141B1 (en) * 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
US20050282198A1 (en) * 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
TR200001263T2 (tr) * 1997-11-07 2000-12-21 Interleukin Genetics, Inc. Kronik tıkayıcı solunum-yolu hastalığının teşhis ve terapötikleri
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
GB2336431B (en) * 1998-04-17 2003-06-25 Johnson & Johnson Medical Ltd Method of analysis of chronic wounds
AU769949B2 (en) * 1998-04-21 2004-02-12 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6733967B1 (en) 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
JP2003500005A (ja) * 1999-02-10 2003-01-07 インターリューキン ジェネティックス インコーポレイテッド ＩＬ−１β遺伝子の突然変異に基づく治療および診断
JP2002540801A (ja) * 1999-04-02 2002-12-03 インタールーキン ジェネティックス インク 間質性肺疾患の危険性の予測
IL147182A0 (en) * 1999-06-30 2002-08-14 Interleukin Genetics Inc Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype
MXPA02002251A (es) * 1999-08-30 2003-08-20 Interleukin Genetics Inc Diagnosticos y terapeuticos para osteoporosis.
US20090023147A1 (en) * 1999-08-30 2009-01-22 Kenneth Kornman Diagnostics and therapeutics for osteoporosis
AU2001264659A1 (en) * 2000-05-17 2001-11-26 Board Of Regents, The University Of Texas System Isolation of genes within sle-1b taht mediate a beak in immune tolerance
US20030124524A1 (en) * 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US20020168639A1 (en) * 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
JP2002345500A (ja) * 2000-12-22 2002-12-03 Pfizer Prod Inc 炎症性障害を発展させる増加したリスクを検出するための方法および試薬
SG143977A1 (en) * 2001-06-05 2008-07-29 Auckland Uniservices Ltd Methods and compositions for assessment of pulmonary function and disorders
EP1409737A4 (en) * 2001-06-15 2005-10-12 Interleukin Genetics Inc METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
CN1753903B (zh) 2001-11-19 2010-05-12 白介素遗传公司 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
KR100924468B1 (ko) 2002-01-25 2009-11-03 인터레우킨 제네틱스, 인코포레이티드 Ｉｌ-1 유전자 집단 및 관련된 염증성 다형성과 일배체형
WO2003100077A2 (en) * 2002-05-20 2003-12-04 Wisconsin Alumni Research Foundation Label-free detection of single nucleotide polymorphisms using surface plasmon resonance imaging
US9388459B2 (en) * 2002-06-17 2016-07-12 Affymetrix, Inc. Methods for genotyping
KR20040001552A (ko) * 2002-06-28 2004-01-07 주식회사 인투젠 디엔에이 결합 단백질 비에 대한 자가항체에 결합할 수있는 단백질을 유효 성분으로 함유하는 전신성 경화증진단용 조성물, 이를 이용한 상기 자가항체의 검출 방법및 전신성 경화증 진단 방법
US20040229228A1 (en) * 2002-07-25 2004-11-18 Northwestern University Il-1 genotype in early kidney allograft rejection
WO2004029618A2 (en) * 2002-09-30 2004-04-08 Novartis Ag Methods to predict cholesterol elevations during immunosuppressant therapy
CN1711361A (zh) * 2002-10-15 2005-12-21 诺瓦提斯公司 预测药物治疗副效应水肿的方法
AU2003291481A1 (en) * 2002-11-11 2004-06-03 Affymetrix, Inc. Methods for identifying dna copy number changes
US10229244B2 (en) 2002-11-11 2019-03-12 Affymetrix, Inc. Methods for identifying DNA copy number changes using hidden markov model based estimations
US7822555B2 (en) * 2002-11-11 2010-10-26 Affymetrix, Inc. Methods for identifying DNA copy number changes
JP2007501627A (ja) 2003-08-08 2007-02-01 インタールーキン ジェネティックス インク 骨粗鬆症のための診断法および治療法
AU2005216298B2 (en) * 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
RU2271827C1 (ru) * 2004-09-28 2006-03-20 Федеральное государственное учреждение"Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи Федерального агенства по здравоохранению и социальному развитию"(ФГУ "СПбНИИ ЛОР Росздрава") Способ определения тактики лечения рекомбинантным цитокином, регулирующим воспаление
WO2006097388A2 (en) * 2005-02-08 2006-09-21 Innogenetics N.V. Nucleic acid variants in the c1qr1 gene associated with altered innate immunity.
US20060269946A1 (en) * 2005-05-10 2006-11-30 Young Robert P Methods and compositions for assessment of pulmonary function and disorders
JP2008545389A (ja) * 2005-05-19 2008-12-18 シナージェンズ バイオサイエンス リミティド 肺機能及び肺障害の評価のための方法及び組成物
AU2006248201A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
EP1888779A4 (en) * 2005-05-20 2009-06-10 Synergenz Bioscience Ltd METHOD FOR THE ANALYSIS OF POLYMORPHISMS AND USES THEREOF
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) * 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) * 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
WO2007023148A2 (en) * 2005-08-22 2007-03-01 Innogenetics N.V. Nucleic acid variants in the lbp gene associated with altered innate immunity
WO2007022590A1 (en) * 2005-08-24 2007-03-01 Genetic Technologies Limited Identification of ancestral haplotypes and uses thereof
US8105775B2 (en) 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US11306351B2 (en) 2005-12-21 2022-04-19 Affymetrix, Inc. Methods for genotyping
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
ES2431671T3 (es) * 2006-11-15 2013-11-27 Interleukin Genetics, Inc. El complejo génico de IL-1 y resistencia a la insulina: polimorfismos asociados, haplotipos y métodos para usarlos
CN101230386B (zh) * 2007-04-28 2011-09-14 廖凌虹 检测CYP2E1基因的单核苷酸多态性位点rs2480256的引物在制造用于评估系统性红斑狼疮易感性的试剂盒的用途
US8200440B2 (en) 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
US20080293589A1 (en) * 2007-05-24 2008-11-27 Affymetrix, Inc. Multiplex locus specific amplification
EP2283156B1 (en) * 2008-05-02 2015-11-11 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
CN102459596B (zh) * 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
EP2539449B9 (en) * 2010-02-26 2018-09-05 Qiagen GmbH Process for parallel isolation and/or purification of rna and dna
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US20120208187A1 (en) * 2010-12-09 2012-08-16 Kenneth Kornman Method and Kit for Determining Severity and Progression of Periodontal Disease
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
WO2014186036A1 (en) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN103397022A (zh) * 2013-07-17 2013-11-20 上海交通大学医学院附属瑞金医院 与Graves病或Graves眼病相关的核苷酸多态性标记及其应用
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
JP2019503176A (ja) 2016-01-12 2019-02-07 インターロイキン ジェネティクス， インコーポレイテッド 処置に対する応答を予測するための方法
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
DE102018104133B4 (de) * 2018-02-23 2025-02-20 Klinikum der Universität München, Anstalt des öffentlichen Rechts Biomarker zur Feststellung einer möglichen Unverträglichkeit gegenüber Metallimplantaten
US12216128B2 (en) 2018-04-12 2025-02-04 Mayo Foundation For Medical Education And Research Methods for guiding therapy decisions in seizure disorders
CN109295211A (zh) * 2018-10-30 2019-02-01 深圳市万众基因转化医学研究院 一种人类斑秃相关基因突变筛查的组合引物及其应用
CN113557036A (zh) 2019-01-18 2021-10-26 奥泽生物疗法公司 基因编辑以改善关节功能
WO2020215051A1 (en) * 2019-04-19 2020-10-22 Rpi Consulting Llc Treatments for pregnancy-related conditions
CA3142662A1 (en) 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19
CA3186119A1 (en) * 2020-07-16 2022-01-20 Orthobio Therapeutics, Inc. Gene editing to improve joint function
US20240327914A1 (en) * 2021-07-08 2024-10-03 Martin Levine Devices, kits, and methods for determining increased susceptibility to and treatment and prevention of periodontitis, alzheimer’s disease, and other conditions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587605T2 (de) * 1984-12-25 1994-03-17 Dainippon Pharmaceutical Co Interleukin-1 und dessen Derivat.
US5582979A (en) * 1989-04-21 1996-12-10 Marshfield Clinic Length polymorphisms in (dC-dA)n.(dG-dT)n sequences and method of using the same
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5681940A (en) * 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
US5993817A (en) * 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5942390A (en) 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
GB9610281D0 (en) * 1996-05-16 1996-07-24 Ralston Stuart H Diagnostic method and apparatus
GB9621129D0 (en) * 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
GB9706359D0 (en) 1997-03-27 1997-05-14 Gemini International Holdings Polymorphisms of an il-1 receptor antagonist gene
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US6733967B1 (en) * 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
EP1409737A4 (en) * 2001-06-15 2005-10-12 Interleukin Genetics Inc METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING
CN1753903B (zh) * 2001-11-19 2010-05-12 白介素遗传公司 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性

Also Published As

Publication number Publication date
NO995803L (no) 2000-01-18
US20080187920A1 (en) 2008-08-07
ATE462800T1 (de) 2010-04-15
ES2342992T3 (es) 2010-07-20
PL337080A1 (en) 2000-07-31
AR016754A1 (es) 2001-08-01
NO995803D0 (no) 1999-11-26
US20040152124A1 (en) 2004-08-05
AU7539898A (en) 1998-12-30
CN1278868A (zh) 2001-01-03
CN1177059C (zh) 2004-11-24
US6268142B1 (en) 2001-07-31
US6706478B2 (en) 2004-03-16
EP0983385B1 (en) 2010-03-31
CA2291731A1 (en) 1998-12-03
AU755107B2 (en) 2002-12-05
IL133128A0 (en) 2001-03-19
ZA984490B (en) 1998-12-02
BR9809183A (pt) 2000-08-01
JP2002500513A (ja) 2002-01-08
US20020146700A1 (en) 2002-10-10
WO1998054359A1 (en) 1998-12-03
GB9711040D0 (en) 1997-07-23
DE69841588D1 (de) 2010-05-12
EP0983385A1 (en) 2000-03-08
TWI236502B (en) 2005-07-21

Similar Documents

Publication Publication Date Title
NO995803L (no) Forutsigelse av inflammatorisk sykdom assosiert med IL-1 genloki-polymorfisme
Hutson et al. Estrogen receptor profiles across tissues from male and female Rattus norvegicus
AR011943A1 (es) Prediccion de enfermedades de la arteria coronaria
Holmström et al. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls
Paradisi et al. Spinocerebellar ataxias in Venezuela: genetic epidemiology and their most likely ethnic descent
Wang et al. Association of the Leukocyte Immunoglobulin‐like Receptor A3 Gene With Neutrophil Activation and Disease Susceptibility in Adult‐Onset Still’s Disease
Kochetova et al. Chemokine gene polymorphisms association with increased risk of type 2 diabetes mellitus in Tatar ethnic group, Russia
Zhou et al. Steric hindrance assay for secreted factors in stem cell culture
Eklund et al. Epistatic effect of C‐reactive protein (CRP) single nucleotide polymorphism (SNP)+ 1059 and interleukin‐1B SNP+ 3954 on CRP concentration in healthy male blood donors
Chinchang et al. Molecular analysis of unknown β-globin gene mutations using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and its application in Thai families with β-thalassemias and β-globin variants
Beutler et al. HLA-H and associated proteins in patients with hemochromatosis
Cardoso et al. T-cell receptor repertoire in hereditary hemochromatosis: a study of 32 hemochromatosis patients and 274 healthy subjects
Brandimarti et al. Investigation on genetic thrombophilic factors in FFPE autopsy tissue from subjects who died from pulmonary embolism
Caplin et al. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms
Mazzola et al. Progressive myoclonus epilepsy caused by a homozygous splicing variant of SLC7A6OS
Shinya et al. A case–control study between the STIM1 gene and hypertensive disorders of pregnancy
Imai et al. The (CTG) n polymorphism in the NOTCH4 gene is not associated with schizophrenia in Japanese individuals
El-Ella et al. CD226 gene polymorphism (rs763361 C> T) is associated with susceptibility to type 1 diabetes mellitus among Egyptian children
Tarnai et al. Effect of C111T polymorphism in exon 9 of the catalase gene on blood catalase activity in different types of diabetes mellitus
Chi et al. Association of− 394C> G and− 420C> G polymorphisms in the RETN gene with T2DM and CHD and a new potential SNP might be exist in exon 3 of RETN gene in Chinese
Kuzmin et al. Complete spectrum of PAH mutations in Tataria: presence of Slavic, Turkic and Scandinavian mutations
Chen et al. Genome-Wide Array Analysis Reveals Novel Genomic Regions and Candidate Gene for Intellectual Disability: X. Chen et al.
Iafusco et al. Molecular diagnosis of MODY3 permitted to reveal a de novo 12q24. 31 deletion and to explain a complex phenotype in a young diabetic patient
Din et al. Mitochondrial uncoupling protein 2 (UCP2) gene polymorphism− 866 G/A in the promoter region is associated with type 2 diabetes mellitus among Kashmiri population of Northern India
Couturier et al. IFIH1-GCA-KCNH7 locus is not associated with genetic susceptibility to multiple sclerosis in French patients